Considering the immunosuppressive effect of GSPT1, the combination of GSPT1 degraders and immunotherapy, including PD‐1 inhibitors, may inhibit tumor growth, activate immune attacks, disrupt immune escape, and enhance anti‐cancer efficacy. Here, PDCD1 is linked to cancer.